2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
European Journal of Cancer2010Vol. 47(1), pp. 8–32
Citations Over TimeTop 1% of 2010 papers
Matti Aapro, Julia Bohlius, David Cameron, Lissandra Dal Lago, J. Peter Donnelly, Nora Kearney, Gary H. Lyman, Ruth Pettengell, Vivianne C. G. Tjan‐Heijnen, Jan Walewski, Damien C. Weber, C. Zielinski
Related Papers
- → Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model(2004)42 cited
- → Preclinical evaluation of a biobetter candidate: Pharmacokinetics and pharmacodynamics of GX‐G3 in healthy and neutropenia‐induced rats(2019)2 cited
- → A Combined Analysis of Average Relative Dose Intensity in the Chemotherapy of Solid Tumors with Pegfilgrastim or Filgrastim Support(2005)3 cited
- → Pegfilgrastim and filgrastim patterns of use in community oncology practices: Results of the ACCEPT study(2005)3 cited
- → 277MO Filgrastim versus pegfilgrastim as primary prevention for reduction of chemotherapy induced febrile neutropenia in Nepal(2022)1 cited